Influenza diagnostics refers to methods and devices that are used to detect influenza virus infections in individuals, including rapid antigen tests, molecular assays (such as RT-PCR), and immunoassays. The market for influenza diagnostics is increasing due to increasing global awareness about infectious diseases, increasing incidence of influenza and increasing outbreaks, increasing demand for rapid and accurate testing, increasing demand for progress in clinical technologies and further emphasis on the identity of initial diseases and the identity of early diseases by governments and healthcare organizations.
Key Growth Drivers and Opportunities
Global Awareness about Infectious Diseases: Global awareness about infectious diseases increases the demand for increasing, accurate, accurate and comprehensive testing. Recent experiences with epidemic such as public health campaigns, media coverage, and Covid-19 have increased the importance of the general population of viral transmission and timely diagnosis. As a result, the healthcare provider and the government are prioritizing investment in clinical infrastructure, rapid testing development and monitoring systems to prevent large -scale outbreaks. This awareness leads to maximum adoption of influenza diagnostic tools in hospitals, clinics, airports and even home settings, which promotes continuous market growth.
Challenges
Influenza diagnostics faces the high cost of advanced testing technologies in the market, low income and clinical equipment limited to clinical equipment in rural areas and the limits of variability in test accuracy-especially with antigen tests that may be false negative. Additionally, the seasonal nature of influenza may demand ups and downs, affecting continuous revenue creation and investment. Regulatory obstacles and skilled personnel need to be widely adopted to adopt molecular diagnosis.
Innovation and Expansion
Quest Diagnostics Gets CDC Contracts to Create Oropouche Virus and H5 Avian Flu Tests
In October 2024, leading diagnostic information services provider Quest Diagnostics announced that the U.S. Centers for Disease Control and Prevention (CDC) has awarded it multiple contracts to support testing and ongoing laboratory readiness for two newly discovered infectious diseases in the Americas.
By guaranteeing that a national commercial laboratory provider may promptly augment public health laboratories in the case of an infectious disease epidemic in humans, the agreements will enhance the country’s readiness for avian influenza and Oropouche viruses.
The FDA Approves the First Over-the-Counter Flu and COVID-19 Test at Home
In February 2023, the first over-the-counter (OTC) at-home diagnostic test that can distinguish and identify influenza A and B, sometimes referred to as the flu, and SARS-CoV-2, the virus that causes COVID-19, was granted an emergency use authorization (EUA) by the U.S. Food and Drug Administration. A single-use at-home test kit, the Lucira COVID-19 & Flu Home Test yields findings from self-collected nose swab samples in around half an hour.
A single-use test for those exhibiting symptoms and indicators typical of a respiratory tract infection, including COVID-19, is the Lucira COVID-19 & Flu Home Test. The test is available without a prescription and may be done entirely at home with nose swab samples that people 14 years of age or older self-collect.
Inventive Sparks, Expanding Markets
Investing in major development strategies for influenza diagnostics manufacturers, investing rapidly and in multiplex test technologies, expanding at home and point-of-care test offerings, forming partnership with healthcare providers and governments, securing regulatory approval quickly and strengthening the global distribution network-in special emergence markets.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.